Antibody therapeutics targeting ion channels: are we there yet?
Antibody therapeutics targeting ion channels: are we there yet?
复制标题
DOI：
10.1038/aps.2012.202
复制
发表时间：
2013-02
期刊：
影响因子：
--
通讯作者：
Han-xiao Sun;Min Li
中科院分区：
文献类型：
--
作者：
Han-xiao Sun;Min Li
技术进步、基因组序列和市场成功的结合正在催化基于抗体的疗法的快速发展。细胞表面受体和离子通道蛋白是众所周知的药物靶点，但后者的成功较少。晶体结构的可获得性、对门控生物物理学的更好理解以及对生理作用的确认，现在构成了以抗体为基础的针对离子通道的疗法来治疗各种疾病的良好基础。
The combination of technological advances, genomic sequences and market success is catalyzing rapid development of antibody-based therapeutics. Cell surface receptors and ion channel proteins are well known drug targets, but the latter has seen less success. The availability of crystal structures, better understanding of gating biophysics and validation of physiological roles now form an excellent foundation to pursue antibody-based therapeutics targeting ion channels to treat a variety of diseases.